ArticleClinical and experimental pediatrics2022
Changes in age-specific seroprevalence of Japanese encephalitis virus and impact of Japanese encephalitis vaccine in Korea.
Article in Clinical and experimental pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Seroprevalence of Japanese Encephalitis Virus, and Immunogenicity of the Vero-Cell Culture-Derived Vaccine in Hematopoietic Stem Cell Transplantation Recipients.Journal of Korean medical science · 2026Article
- Advances and Challenges in Vaccination and Therapeutic Strategies Against Japanese Encephalitis Virus.Pathogens (Basel, Switzerland) · 2025Review
- Immunogenicity, immune persistence, and safety of japanese encephalitis vaccine schedules among adults in Ningxia, China.NPJ vaccines · 2025Article
- Genetic shifts of Japanese encephalitis virus (JEV) in mosquitoes in the Republic of Korea, 2017-2022.PLoS neglected tropical diseases · 2025Article
- Epidemiological Features, Clinical Symptoms, and Environmental Risk Factors for Notifiable Japanese Encephalitis in Taiwan From 2008 to 2020: Retrospective Study.JMIR public health and surveillance · 2025Article
- Characterization of a Small Plaque Variant Derived from Genotype V Japanese Encephalitis Virus Clinical Isolate K15P38.Journal of microbiology and biotechnology · 2024Article
- Generation of rescued Japanese encephalitis virus genotype 1 from infectious full-size clone using reverse genetics.Heliyon · 2024Article
- Japanese encephlu emergence in Australia: the potential population at risk.Annals of medicine and surgery (2012) · 2024Review
- Epidemiology and risk factors of Japanese encephalitis in Taiwan, 2010-2022.PLoS neglected tropical diseases · 2023Article
- Japanese Encephalitis among Adults: A Review.The American journal of tropical medicine and hygiene · 2023Review
- New Detection of Locally Acquired Japanese Encephalitis Virus Using Clinical Metagenomics, New South Wales, Australia.Emerging infectious diseases · 2023Article
- Machine learning reveals neutrophil-to-lymphocyte ratio as a crucial prognostic indicator in severe Japanese encephalitis patients.Frontiers in neurology · 2023Article
- Emerging Japanese Encephalitis Virus Genotype V in Republic of Korea.Journal of microbiology and biotechnology · 2022Review
- Importance of maintaining a high childhood vaccination rate and surveillance program against Japanese encephalitis in Korea.Clinical and experimental pediatrics · 2022Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Japanese encephalitis (JE) virus is the leading cause of vaccine-preventable encephalitis in Asia. Since the introduction of a universal JE vaccination program and urbanization of Korea, the incidence of JE has dramatically decreased in Korea. However, recent JE cases have occurred, predominantly among unvaccinated adults and with a shift in age distribution. Here we aimed to review the changes in age-specific JE seroprevalence over time and discuss the implications of JE vaccination programs in Korea. Following the last epidemic in 1982-1983, mandatory vaccination for all children aged 3-15 years was conducted annually until 1994. However, JE has reemerged, predominantly affecting unvaccinated adults aged 40 years or older and demonstrating a shift in age distribution toward older populations. The age-specific seroprevalence of the JE virus in Korea has changed noticeably over time. Seropositivity in children and adolescents increased from 10%-59% in the 1970s to 90%-92% in the 1980s after the implementation of the JE vaccination program and increased further to 98% in 2012. No age-specific difference in the seroprevalence of JE was found, and appropriate levels of immunity to JE were maintained for all age groups. Continuous surveillance of the seroprevalence of JE is essential to establish a proper immunization policy in Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.